美国1型和2型糖尿病成人中的肥胖与慢性肾脏病
研究纳入2004至2018年Geisinger健康系统的1型和2型糖尿病患者,评估肥胖、低eGFR和白蛋白尿的趋势。1型糖尿病肥胖率从32.6%升至36.8%,2型稳定在约60%。校正年龄后1型糖尿病低eGFR患病率高于2型,肥胖与两者低eGFR风险升高相关。
要点
- 1型糖尿病肥胖率从2004年32.6%升至2018年36.8%,2型稳定在约60%。
- 2018年粗低eGFR患病率2型30.6%高于1型16.1%,校正年龄后1型16.2%高于2型9.3%。
- 肥胖与1型糖尿病低eGFR风险升高相关(AOR=1.52,95%CI 1.12-2.08)。
核心结论
- 1型糖尿病患者中肥胖呈上升趋势,且与慢性肾脏病风险升高相关。
- 校正年龄后,1型糖尿病的慢性肾脏病负担超过2型糖尿病,提示需提高警惕并评估肾脏保护药物。
研究设计与样本
- 研究纳入2004至2018年Geisinger健康系统的所有1型糖尿病患者,并纳入2型糖尿病患者作为比较。
- 评估肥胖(体重指数≥30 kg/m2)、低估算肾小球滤过率(eGFR≤60 mL/min/1.73m2)和白蛋白尿(尿白蛋白与肌酐比值≥30 mg/g)的趋势。
- 采用多变量逻辑回归评估2018年肥胖与慢性肾脏病的独立关联。
主要发现
- 1型糖尿病患者比2型糖尿病患者年轻(中位年龄39岁 vs 62岁)。
- 1型糖尿病肥胖率从2004年32.6%升至2018年36.8%,2型糖尿病肥胖率稳定在约60%。
- 低eGFR粗患病率在所有年份2型均高于1型(如2018年30.6% vs 16.1%),但校正年龄差异后所有年份1型均高于2型(如2018年16.2% vs 9.3%)。
- 肥胖与1型糖尿病低eGFR风险升高相关(校正比值比AOR=1.52,95%CI 1.12-2.08)。
- 肥胖与2型糖尿病低eGFR风险升高相关(AOR=1.29,95%CI 1.23-1.35)。
临床怎么用
- 作者认为,1型糖尿病中慢性肾脏病负担超过2型糖尿病,提示需提高警惕并评估肾脏保护药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Obesity is a global public health challenge and strongly associated with type 2 diabetes (T2D), but its burden and effects are not well understood in people with type 1 diabetes (T1D). Particularly, the link between obesity and chronic kidney disease (CKD) in T1D is poorly characterized. RESEARCH DESIGN AND METHODS: We included all T1D and, for comparison, T2D in the Geisinger Health System from 2004 to 2018. We evaluated trends in obesity (body mass index ≥ 30 kg/m2), low estimated glomerular filtration rate (eGFR) (≤60 mL/min/1.73m2), and albuminuria (urine albumin-to-creatinine ratio ≥ 30 mg/g). We used multivariable logistic regression to evaluate the independent association of obesity with CKD in 2018. RESULTS: People with T1D were younger than T2D (median age 39 vs 62 years). Obesity increased in T1D over time (32.6% in 2004 to 36.8% in 2018), while obesity in T2D was stable at ~60%. The crude prevalence of low eGFR was higher in T2D than in T1D in all years (eg, 30.6% vs 16.1% in 2018), but after adjusting for age differences, prevalence was higher in T1D than T2D in all years (eg, 16.2% vs 9.3% in 2018). Obesity was associated with increased odds of low eGFR in T1D [adjusted odds ratio (AOR) = 1.52, 95% CI 1.12-2.08] and T2D (AOR = 1.29, 95% CI 1.23-1.35). CONCLUSIONS: Obesity is increasing in people with T1D and is associated with increased risk of CKD. After accounting for age, the burden of CKD in T1D exceeded the burden in T2D, suggesting the need for increased vigilance and assessment of kidney-protective medications in T1D.
引用
- Wallace AS, Chang AR, Shin JI, et al. Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2022. PMID: 35080610. doi:10.1210/clinem/dgab927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。